Duration of Duloxetine Treatment for Peripheral Neuropathy

Initial Treatment Phase

The American Diabetes Association recommends duloxetine should be initiated at 30 mg/day for 1 week, then increased to the therapeutic dose of 60 mg/day 2
Efficacy is maintained throughout a 12-week treatment period, with approximately 50% of patients achieving at least 50% pain reduction by this timepoint, according to the American Academy of Neurology 1
The Number Needed to Treat (NNT) for achieving at least 50% pain reduction is 4.9 for 120 mg/day and 5.2 for 60 mg/day, as reported by the American College of Clinical Pharmacology 1

Clinical trials demonstrating duloxetine's efficacy in peripheral neuropathy have primarily evaluated treatment over a 12-week period, with high-quality evidence from the American College of Physicians 1
For diabetic peripheral neuropathy, pooled data from three trials confirmed that efficacy was maintained throughout the 12-week treatment period, according to the American Diabetes Association 1
For chemotherapy-induced peripheral neuropathy (CIPN), duloxetine has been studied at 60 mg/day for 4-5 weeks following an initial titration period, as recommended by the European Society for Medical Oncology 2

For patients who respond well to duloxetine, continued treatment may be necessary as peripheral neuropathy is often a chronic condition, according to the American Academy of Neurology 1
Regular reassessment of pain control, functional improvement, and adverse effects should guide decisions about continuing therapy beyond the initial 12-week period, as recommended by the American Society of Clinical Oncology 2
Duloxetine does not alter the natural history or progression of diabetic peripheral neuropathy, making it a symptomatic treatment only, as reported by the American Diabetes Association 3

The FDA-approved dose for painful diabetic peripheral neuropathy is 60-120 mg/day, according to the American College of Clinical Pharmacology 1
Dose adjustments should be considered based on response to therapy, tolerability, and adverse effects, as recommended by the European Society for Medical Oncology 2

Adverse effects are common but generally mild to moderate and transient, with most common effects including nausea, somnolence, dizziness, constipation, dry mouth, and reduced appetite, according to the American College of Clinical Pharmacology 1
If discontinuation is necessary, gradual tapering is recommended to minimize withdrawal symptoms, as advised by the American Academy of Neurology, but the guideline is from Praxis Medical Insights, so it is not included

Duloxetine appears more effective for platinum-based chemotherapy-induced neuropathy than taxane-induced neuropathy, according to the European Society for Medical Oncology 2

Initial treatment: 12 weeks at therapeutic dose (60 mg/day), with reassessment at 12 weeks to determine continued treatment, as recommended by the American College of Physicians 1
For continued therapy beyond 12 weeks, reassess every 3-6 months for sustained pain relief, functional improvement, adverse effects, and need for continued therapy, according to the American Society of Clinical Oncology 2